Kenny John P.'s Form 4 filing
Meridian Bioscience Inc · filed Jun 28, 2022
- Accession no.
- 0001127602-22-018184
- Filed
- Jun 28, 2022
- Trade date
- Jun 24-27, 2022
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 4 non-derivative transactions and 2 derivative transactions. Open-market sales total $2.27M. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Kenny John P.CIK 0001719325 | Director, Officer (Chief Executive Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 24, 2022 | Common Stock | MOption exerciseAcquired | +13,559 | $10.10 | +$136,945.9 | 278,690 | Direct | |
| Jun 24, 2022 | Common Stock | SSaleDisposed | −13,559 | $30.00F2 | −$406,770 | 265,131 | Direct | |
| Jun 27, 2022 | Common Stock | MOption exerciseAcquired | +61,437 | $10.10 | +$620,513.7 | 326,568 | Direct | |
| Jun 27, 2022 | Common Stock | SSaleDisposed | −61,437 | $30.39F4 | −$1,867,070.43 | 265,131 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 24, 2022 | Common Stock | MOption exerciseDisposed | −13,559 | $0.00 | $0 | 127,476 | Direct | |
| Jun 27, 2022 | Common Stock | MOption exerciseDisposed | −61,437 | $0.00 | $0 | 66,039 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $30.00 to $30.11. The Reporting Person undertakes to provide full pricing information if requested by the Securities and Exchange Commission, the issuer or a security holder of the issuer.
Referenced by the price of 1 transaction in Table I.
- F4
The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $30.00 to $30.76. The Reporting Person undertakes to provide full pricing information if requested by the Securities and Exchange Commission, the issuer or a security holder of the issuer.
Referenced by the price of 1 transaction in Table I.